NCT05086627View on ClinicalTrials.gov

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

July 30, 2024

Study Completion Date

August 20, 2024

Conditions
Locally Advanced Rectal Cancer
Interventions
DRUG

Tislelizumab

Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).

RADIATION

Short-course radiotherapy

Patients were treated with short-course neoadjuvant radiotherapy

DRUG

Capecitabine+Oxaliplatin

Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).

Trial Locations (1)

050011

Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER

NCT05086627 - Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter